Bob Soh

Bob Soh has had a diverse work experience in various roles and companies. Bob started their career at Royal Melbourne Hospital, Royal North Shore Hospital, and Liverpool Hospital in the Department of Surgery (Neurosurgery) from 2007 to 2012. Bob then worked at Nucleus Network as a Clinical Triallist and Investigator from December 2011 to January 2016. In 2012, they also worked at the University of Melbourne as an Examiner and Demonstrator until June 2014. From 2015 to 2020, Bob Soh served as the Acting Chief Executive Officer of Cardiora. Bob joined EBR Systems Inc. as a Board Observer in 2017 and held that position until December 2021. In 2020, they became a Director at Glyscend Incorporated. In 2022, they started working at Brandon Capital, initially as an Investment Associate from 2016 to 2019, then as an Investment Manager from 2019 to 2022, and currently as a Senior Investment Manager. Additionally, in 2022, they also became an Alternate Director at Entact Bio.

Bob Soh began their education at the University of Melbourne in 2001, where they pursued a Bachelor of Medicine and Bachelor of Surgery degree. During their time at the university, from 2001 to 2003, they also completed a Bachelor of Medical Science. In 2011, Bob Soh briefly attended the University of Melbourne again, obtaining a Graduate Diploma in Surgical Anatomy. Continuing their education, they completed the Australian Institute of Company Directors program and became a Graduate of the Australian Institute of Company Directors in 2016.